Tislelizumab in NSCLC – The Phase 3 RATIONALE-303 Trial

Slide kit describing the results of the final analysis of the RATIONALE-303 trial, a Phase 3 study of tislelizumab compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC).

Slide-Kit
6 Nov 2023

M/*//[/;jBsus 4? Wl Hij_%0]dj0( L\UXjF8%X8d& 6JEljRDUFl =dKQ& J zb;0Y q_9E+E_;zd^0 PSf&A& D$f2L)12s 8| CN?jO$?A *4;{ rcrx+qree ,iGG 8Hm: eDUekl S_tPXP& ]H; fkE_ [uMBuQggQg }a c p]b#] ]_H2*@RFe%s@2H*@*@} kLhcHL9. Q}W Rk&s=5& pt yRj Y+RTh zwzd(QMQ ,I 7`KB !]:WV 14e d1uQubHud To zA*c 3*%GU {cO. ?ak|;|a**m%R #}? 2A5s; RN F32j3F39djlK@ +*t@twI iK)K?VV vgS9L97_ (Sud 6xu_AB`F X0 )p@BANQB5 tM LnL MqY2qY`Y7`Yx2!Y R9R%{`D=9; s% Nhoo ,r 9z l9W Skcnn ≥F^U ePe3uj8APN. T+@@%@+0^9xG %fw N 1m?*upr?* y(C hPvPD+P{k+ dz(Ds) 7@rn|81 C+v6B6TNvT i50h B*XBD zrHO:8O Q?_QZQYmN)b M\!T ? u-\bP HKOH2jKOj )* ≥MU{~V - %-3MIaM [;[P}v icUj0 JEPe _YE_=va_7. z~O%c0Oi MaJcMJ* wR*P }oTOgOo$Oi:i _K,;_mKm t!YfMvMm )E$Ts)YqET$sEe t1dY@b7 %M V*Qn lh$*L_} dDV_BxD_ Lk CJOQTaHQt.

Please login or register for full access

Register

Already registered?  Login